Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts-Reference-Cited by-同舟云学术

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Published:2021-09-18 Issue:11 Volume:35 Page:1217-1232
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Sharmin Sifat,Lefort Mathilde,Andersen Johanna Balslev,Leray Emmanuelle,Horakova Dana,Havrdova Eva Kubala,Alroughani Raed,Izquierdo Guillermo,Ozakbas Serkan,Patti Francesco,Onofrj Marco,Lugaresi Alessandra,Terzi Murat,Grammond Pierre,Grand’Maison Francois,Yamout Bassem,Prat Alexandre,Girard Marc,Duquette Pierre,Boz Cavit,Trojano Maria,McCombe Pamela,Slee Mark,Lechner-Scott Jeannette,Turkoglu Recai,Sola Patrizia,Ferraro Diana,Granella Franco,Prevost Julie,Maimone Davide,Skibina Olga,Buzzard Katherine,Van der Walt Anneke,Van Wijmeersch Bart,Csepany Tunde,Spitaleri Daniele,Vucic Steve,Casey Romain,Debouverie Marc,Edan Gilles,Ciron Jonathan,Ruet Aurélie,De Sèze Jérôme,Maillart Elisabeth,Zephir Hélène,Labauge Pierre,Defer Gilles,Lebrun-Frénay Christine,Moreau Thibault,Berger Eric,Clavelou Pierre,Pelletier Jean,Stankoff Bruno,Gout Olivier,Thouvenot Eric,Heinzlef Olivier,Al-Khedr Abullatif,Bourre Bertrand,Casez Olivier,Cabre Philippe,Montcuquet Alexis,Wahab Abir,Camdessanché Jean-Philippe,Maurousset Aude,Patry Ivania,Hankiewicz Karolina,Pottier Corinne,Maubeuge Nicolas,Labeyrie Céline,Nifle Chantal,Laplaud David,Koch-Henriksen Niels,Sellebjerg Finn Thorup,Soerensen Per Soelberg,Pfleger Claudia Christina,Rasmussen Peter Vestergaard,Jensen Michael Broksgaard,Frederiksen Jette Lautrup,Bramow Stephan,Mathiesen Henrik Kahr,Schreiber Karen Ingrid,Magyari Melinda,Vukusic Sandra,Butzkueven Helmut,Kalincik Tomas^ORCID,

Funder

National Health and Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40263-021-00860-7.pdf

Reference29 articles.

1. Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.

2. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.

3. Barbin L, Rousseau C, Jousset N, et al. Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study. Neurology. 2016;86(8):771–8.